Aurora Cannabis reiterates call for shareholders to reject revised Curaleaf bid
ACB•Aurora Cannabis’ board reaffirmed its opposition to Curaleaf’s revised offer for all outstanding common shares, citing significant undervaluation. The offer remains open until December 4, 2026, and a special committee is exploring third-party transactions or continued independence.
1. Board maintains opposition
Aurora Cannabis’ board reaffirmed its opposition to Curaleaf’s revised offer, which was revised on October 6, 2026, and remains open until December 4, 2026. The board said the offer significantly undervalues the company and noted that the higher consideration consists principally of Curaleaf shares, while a significant portion of the cash consideration would come from Aurora’s balance sheet.
2. Committee reviews options
A special committee is exploring third-party transactions or continued independence. Multiple parties are reviewing information under confidentiality agreements.
